Abstract

IntroductionMelanoma is the most lethal malignancy of the skin. The Cancer Genome Atlas (TCGA) Network proposed a molecular classification of melanoma, consisting in three subtypes: keratin-high, immune-high and membrane-low. However, this classification has not been translated into therapeutic advances yet. The aim of this study is to characterise molecular differences of melanoma at biological and molecular levels and propose a novel molecular classification with clinical impact.Material and methodsA novel approach based on the existence of different molecular informative layers was used in this study to establish independent sets of information. A probabilistic graphical model, followed by successive sparse k-means and consensus cluster analyses were used to classify melanoma tumour samples from the TCGA cohort. Then, molecular classification was validated in another public cohort: GSE65904.Results and discussionsWe established that there were at least two different kinds of molecular information: an immune layer and a histological layer. Immune high and immune low groups were established based on immune layer information. Keratin low-proliferation low, melanogenesis high-membrane low, melanogenesis low-membrane high and keratin high groups were established based on molecular layer information. This suggests that the information related to the immune system is independent from other molecular features and is distributed among the groups established by the TCGA classification. Besides, the immune and histological assignments showed different clinical outcomes in another dataset, identifying two immune groups with prognostic value.ConclusionIn this work we proposed a novel analytical approach based on informative molecular layers. In this way, two independent classifications, an immune-based and a histological-based classification, were established. Immune classification showed prognostic value in an independent cohort. Besides, the histological and the immune layers may deserve additional research for define new potential targeted therapies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.